Third Harmonic Bio Inc（THRD）资讯与事件THRDThird Harmonic Bio Inc

Third Harmonic Bio reports updated THB335 data, initiates THB335 sale

As part of the previously announced ongoing Phase 2 readiness activities, the Company recently completed an additional 14-day multiple ascending dose cohort in the Phase 1 clinical trial of THB335 in healthy volunteers. The cohort evaluated the pharmacokinetics, pharmacodynamics and safety of THB335 at a once-daily dose of 100mg utilizing a new drug product capsule formulation that is intended for use in future clinical development. The 100mg QD dose showed pharmacokinetics and pharmacodynamics largely consistent with the 164mg dose level evaluated in a prior MAD cohort of the Phase 1 clinical trial, with mean plasma trough exposures exceeding the 90% inhibition concentration of KIT by over six-fold, and an 85% mean reduction from baseline of serum tryptase, a biomarker of mast cell activation. All adverse events were mild, with the exception of one moderate adverse event of neutrophil reduction. There were no adverse events due to hemoglobin reduction, nor any other clinically significant laboratory value changes reported in the cohort. One subject experienced mild hair color change and mild taste loss, which resolved during the follow-up period. The Company has now completed all clinical, toxicology and manufacturing activities to support a Phase 2 clinical trial of THB335 for the treatment of chronic spontaneous urticaria, and it plans to submit imminently a regulatory filing with the US Food and Drug Administration to seek clearance for trial initiation. The Company also announced it is initiating a sale process of THB335 and related intellectual property.

Third Harmonic Bio receives stockholder approval of plan of liquidation

Third Harmonic Bio announced that its stockholders overwhelmingly approved the previously proposed Plan of Liquidation and Dissolution at the Company's Annual Meeting of Stockholders held on June 5, 2025. In addition, The Company also announced the results of a recently completed additional cohort in its Phase 1 clinical trial of its oral wild-type KIT inhibitor development candidate, THB335, and that it is initiating the sale process of THB335 as part of the Plan of Dissolution. Subject to final approval by its Board of Directors, the Company currently expects to finalize the Plan of Dissolution and make the initial distribution to stockholders in the third quarter of 2025. The proposal to adopt the Plan of Dissolution received the affirmative vote of holders of 99.9% of the shares casting votes and 83.7% of the Company's total outstanding common shares. Based on the information currently available to the Company, the Company estimates that the total distributions will be in the range between approximately $5.30 and $5.44 per share of common stock. The initial distribution, currently expected in the third quarter of 2025, is estimated to be between approximately $5.30 and $5.35 per share of common stock. These estimates do not include cash that may become available for distribution from the proceeds from any sales of the Company's remaining assets and intellectual property, including but not limited to a sale of THB335. The amount distributable, however, may vary substantially from any estimate provided by the Company based on a number of factors.

Third Harmonic Bio sees initial distribution of $5.13-$5.33 from liquidation

On April 10, the Board of Directors unanimously approved the dissolution and liquidation of the Company, subject to stockholder approval, pursuant to the Plan of Dissolution. The Company intends to hold its annual meeting of stockholders on June 5, 2025, at which it will seek stockholder approval of the Plan of Dissolution. If the Company's stockholders approve the Plan of Dissolution, the Company currently intends to file a Certificate of Dissolution, delist its shares of common stock from The Nasdaq Global Select Market, satisfy or resolve its remaining liabilities and obligations, including but not limited to contingent liabilities and claims and costs associated with the dissolution and liquidation, make reasonable provisions for unknown claims and liabilities, and attempt to convert all of its remaining assets into cash or cash equivalents. Upon the filing of the Certificate of Dissolution, the Company intends to cease trading in its common stock, close its stock transfer books and discontinue recording transfers of shares of its capital stock, in accordance with applicable law. The Company will establish a reserve, which will be used to pay all expenses and other known, non-contingent liabilities and obligations, and will include reasonable provision for future expenses of liquidation and contingent and unknown liabilities as required by Delaware law. The Company currently expects that its existing capital resources together with the anticipated net proceeds from the sale of certain clinical assets will enable it to meet its remaining liabilities and obligations with sufficient reserves. Based on the information currently available to the Company and if the stockholders approve the dissolution, the Company estimates that the total distribution will be in the range between approximately $246.6 million and $259.8 million, or approximately $5.13 and $5.42 per share of common stock. The Company also estimates that the initial distribution will be in the range between approximately $246.6 million and $255.4 million, or approximately $5.13 and $5.33 per share of common stock, which it expects to be distributed following the filing of the Certificate of Dissolution, currently expected in the third quarter of 2025. These estimates do not include cash that may become available for distribution from the proceeds from any sales of the Company's remaining assets and intellectual property, including but not limited to a sale of THB335. The amount distributable, however, may vary substantially from any estimate provided by the Company based on a number of factors.